CARVYKTI is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, ...

CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)- directed genetically modified autologous T cell immunotherapy indicated for the.

CARVYKTI is authorized for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including ...

Role of the medicinal product: CARVYKTI (ciltacabtagene autoleucel) is a 4th-line or subsequent treatment for relapsed and refractory multiple myeloma, among ...

Summary of product characteristics (SmPC), labelling and package leaflet (PL), download. Link to the European Medicines Agency's (EMA) product information ...

CARVYKTI infusion should be administered 5 to 7 days after the start of the lymphodepleting regimen. For additional guidance see corresponding SmPC of.

CARVYKTI ® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at ... About CARVYKTI · Find a certified treatment center · Resources & Support

22 апр. 2024 г. · CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who ...

Medicinal product database including all medicinal products for human and veterinary use authorised in Belgium.

CARVYKTI (ciltacabtagene autoleucel) est un médicament à base de cellules autologues génétiquement modifiées, constitué de lymphocytes T transduits ex vivo ...